HANSHOW
28.2.2024 10:59:29 CET | Business Wire | Press release
Hanshow, a leader in retail technology innovation, today unveiled a series of Green Store Solutions, designed to accelerate the retail industry towards a sustainable future. Complementing this new product, Hanshow has also released a comprehensive Green Digitalization Report alongside tech partners Microsoft, Intel, and E Ink.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240223583112/en/
Hanshow at EuroCIS 2024 (Photo: Business Wire)
The Polaris Pro Electronic Shelf Labels (ESL) series stands out with its high screen-to-body ratio, multi-color display capabilities, and user-replaceable battery system designed for longevity, embodying Hanshow's commitment to sustainability. This advanced ESL solution is set to reduce paper waste, improve pricing accuracy, and enhance the overall aesthetic of modern retail environments.
Building on the innovative leadership of the Polaris Pro, Hanshow's Green Store Solutions extend beyond ESLs to include dynamic in-store marketing and AI-driven solutions. These innovations optimize store performance through targeted promotions, precise inventory management, and real-time data insights, facilitating smarter, greener operations.
To push the boundaries of what is possible in retail further, Hanshow integrates GenAI technology into its digital retail Solutions, enhancing operational efficiency and customer experiences. This adoption of GenAI simplifies complex processes and decision-making, making retail operations more efficient and intuitive. GenAI serves as an assistant to both store associates and customers, enabling easier navigation, personalized shopping experiences, and enhanced staff productivity.
Hanshow’s authoritative Green Digitalization Report, highlighting the dual benefits of digitalization and sustainability. The report, produced in cooperation with Microsoft, Intel, and E Ink, offers a deep dive into how retailers can use green digitalization as a double engine for growth, marrying eco-efficiency with cutting-edge innovation.
"Hanshow is proud to be at the forefront of the movement towards a greener, more digital future for retail," said Liangyan Li, SVP and Head of Global Sales at Hanshow. "With the introduction of the Polaris Pro series and our comprehensive Green Store Solutions, including our pioneering work on GenAI, we are paving the way for retailers to operate sustainably without compromising on customer satisfaction or operational excellence."
To further promote the many exciting ways in tech technology is laying a stronger foundation for sustainability in the retail industry, Hanshow’s Green Digitalization Report outlines actionable strategies to integrate sustainability into core business operations through innovative technologies. The report was released jointly with important contributions from industry partners such as Microsoft, Intel, and E Ink, and emphasizes myriad ways in which new technological advancements in AI, IOT, and data-driven decision-making will optimize management, reduce resource waste and store costs, improve associates’ work productivity and job satisfaction, and more accurately track and adjust customer experiences both in-store and online, all while helping retailers to meet sustainability targets.
Retailers eager to explore the Polaris Pro series, the suite of Green Store Solutions, and the findings of the Green Digitalization Report are invited to connect with Hanshow's team. Demonstrations and consultations are available to showcase how these initiatives can be seamlessly incorporated into existing retail frameworks.
About Hanshow
Hanshow is one of the global leaders in the development and manufacturing of electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores across more than 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240223583112/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom